These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 6703854)

  • 1. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease.
    Raskind MA; Peskind ER; Halter JB; Jimerson DC
    Arch Gen Psychiatry; 1984 Apr; 41(4):343-6. PubMed ID: 6703854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease.
    Raskind MA; Peskind ER; Holmes C; Goldstein DS
    Biol Psychiatry; 1999 Sep; 46(6):756-65. PubMed ID: 10494443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease.
    Lawlor BA; Bierer LM; Ryan TM; Schmeidler J; Knott PJ; Williams LL; Mohs RC; Davis KL
    Biol Psychiatry; 1995 Aug; 38(3):185-8. PubMed ID: 7578662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNS 3-methoxy-4-hydroxyphenylglycol: its peripheral assessment by isotopic dilution and theoretical significance.
    Tang SW; Stancer HC; Warsh JJ
    Brain Res Bull; 1978; 3(6):669-74. PubMed ID: 400926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic autonomic failure: CSF and plasma 3-methoxy-4-hydroxyphenylglycol.
    Polinsky RJ; Jimerson DC; Kopin IJ
    Neurology; 1984 Jul; 34(7):979-83. PubMed ID: 6539879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clonidine on central and peripheral catecholamine metabolism.
    Martin PR; Ebert MH; Gordon EK; Linnoila M; Kopin IJ
    Clin Pharmacol Ther; 1984 Mar; 35(3):322-7. PubMed ID: 6199153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration.
    Elrod R; Peskind ER; DiGiacomo L; Brodkin KI; Veith RC; Raskind MA
    Am J Psychiatry; 1997 Jan; 154(1):25-30. PubMed ID: 8988954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type.
    Martignoni E; Blandini F; Petraglia F; Pacchetti C; Bono G; Nappi G
    J Neural Transm Park Dis Dement Sect; 1992; 4(3):191-205. PubMed ID: 1320891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and metabolism of MHPG-CD3 in humans: plasma MHPG as the principal pathway of norepinephrine metabolism and as an important determinant of CSF levels of MHPG.
    Kopin IJ; Blombery P; Ebert MH; Gordon EK; Jimerson DC; Markey SP; Polinsky RJ
    Adv Biochem Psychopharmacol; 1984; 39():57-68. PubMed ID: 6464833
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative importance of 3-methoxy-4-hydroxyphenylglycol and 3,4-dihydroxyphenylglycol as norepinephrine metabolites in rat, monkey, and humans.
    Elsworth JD; Roth RH; Redmond DE
    J Neurochem; 1983 Sep; 41(3):786-93. PubMed ID: 6875564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine.
    Peskind ER; Wingerson D; Murray S; Pascualy M; Dobie DJ; Le Corre P; Le Verge R; Veith RC; Raskind MA
    Arch Gen Psychiatry; 1995 Sep; 52(9):774-82. PubMed ID: 7654129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between plasma and cerebrospinal fluid norepinephrine and dopamine metabolites in a nonhuman primate.
    Greene KA; Faull KF
    J Neurochem; 1989 Oct; 53(4):1007-13. PubMed ID: 2769251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between plasma MHPG and NE: employing regression models in estimating centrally derived MHPG and peripheral NE turnover rate in panic disorder.
    Gurguis GN; Uhde TW
    J Psychiatr Res; 1998; 32(1):11-7. PubMed ID: 9693996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunction of norepinephrine and its metabolites in Alzheimer's dementia - A review with meta-analysis.
    Portela Moreira I; Henriques T; Vieira-Coelho MA; Guimarães J
    Ageing Res Rev; 2023 Jan; 83():101784. PubMed ID: 36368648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of free MHPG in rat cerebrospinal fluid with free and conjugated MHPG in brain tissue: effects of drugs modifying noradrenergic transmission.
    Scheinin H; MacDonald E; Scheinin M
    Eur J Pharmacol; 1986 Sep; 129(1-2):113-21. PubMed ID: 2876902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol and norepinephrine levels in alcohol withdrawal. Correlations with clinical signs.
    Hawley RJ; Major LF; Schulman EA; Linnoila M
    Arch Gen Psychiatry; 1985 Nov; 42(11):1056-62. PubMed ID: 4051683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates.
    Elsworth JD; Redmond DE; Roth RH
    Brain Res; 1982 Mar; 235(1):115-24. PubMed ID: 7188317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on 3-methoxy-4-hydroxyphenylglycol (MHPG) and 3,4-dihydroxyphenylglycol (DHPG) levels in human urine, plasma and cerebrospinal fluids, and their significance in studies of depression.
    Tsuji M; Yamane H; Yamada N; Iida H; Taga C; Myojin T
    Jpn J Psychiatry Neurol; 1986 Mar; 40(1):47-56. PubMed ID: 3773351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF and plasma MHPG, and CSF MHPG index: pretreatment levels in diagnostic groups and response to somatic treatments.
    Sharma RP; Javaid JI; Faull K; Davis JM; Janicak PG
    Psychiatry Res; 1994 Jan; 51(1):51-60. PubMed ID: 7910975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.